Determination of the Efficacy of Different Medications for Idiopathic Rhinitis Clinical Trial
Official title:
Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis
| Verified date | June 2019 |
| Source | Beijing Tongren Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.
| Status | Recruiting |
| Enrollment | 80 |
| Est. completion date | March 31, 2020 |
| Est. primary completion date | December 31, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Not younger than 18 years old - Diagnosed as idiopathic rhinitis - Signed and volunteered for the study Exclusion Criteria: - Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps - Allergic to the medicines about to study - Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Tongren Hospital | Beijing | Beijing |
| China | Yifan Meng | Beijing | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Beijing Tongren Hospital | Beijing Institute of Otolaryngology, Shanghai Johnson & Johnson Pharmaceuticals, Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Relief of bothersome symptoms | Determined by change of visual analog scale for symptoms | 2 weeks |